How Does Retatrutide Work? The Triple-Agonist Mechanism Explained

Retatrutide (development code LY3437943) is an investigational Eli Lilly peptide that acts on three receptors at once — which is why it's described as a "triple agonist." Understanding how it works comes down to understanding what each of those three receptors does, and why combining them is different from the GLP-1 and dual-agonist drugs already on the market.

Retatrutide is not an approved medication. It remains investigational and is being studied in clinical trials. Nothing here is medical advice.

The three receptors retatrutide targets

In the discovery paper that introduced the molecule, researchers described LY3437943 as a triple agonist at the glucagon receptor (GCGR), the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R). Each of those receptors has a distinct, well-established physiological role:

The GLP-1 and GIP arms are the same pathways targeted by tirzepatide, the approved dual agonist. The glucagon arm is the addition that makes retatrutide distinct. For the side-by-side, see tirzepatide vs retatrutide.

Why glucagon agonism is the differentiator

Adding glucagon-receptor activity is the central design idea, and it points at a different lever for weight loss. GLP-1 and GIP largely reduce calorie intake by curbing appetite and slowing digestion. Glucagon works on the other side of the energy-balance equation: it is associated with increased energy expenditure and with hepatic fat oxidation.

In the discovery work, the researchers put it directly — in animal models, body-weight loss "was augmented by the addition of GCGR-mediated increases in energy expenditure to GIPR- and GLP-1R-driven calorie intake reduction." That is the "two-sided" rationale: cut intake and raise expenditure.

There's an important nuance here. The energy-expenditure contribution is established in mice and biologically plausible in people, but the precise human mechanism is not settled. Reviews of glucagon physiology note that acute glucagon does raise energy expenditure in human studies, but data on chronic glucagon administration in humans is scarce, and the effect is tied to hepatic signaling rather than a simple "burns fat by activating brown fat" story. So the honest framing is: the receptor difference is a fact; the size of glucagon's contribution to retatrutide's weight loss in humans is still being worked out.

A glucagon component also explains why blood-sugar control has to be balanced carefully — glucagon tends to raise glucose, while the GLP-1 and GIP arms enhance insulin secretion and offset it. In trials that net balance has favored improved glycemic control, which you can read about in retatrutide's results.

The molecular design

Retatrutide is a synthetic single-chain peptide. Structural work shows it adopts a single continuous helix that engages the receptors, and that, like semaglutide and tirzepatide, it is acylated with a fatty-diacid moiety attached to a lysine residue. That fatty-acid tail lets the peptide bind reversibly to albumin in the bloodstream, which slows its clearance and extends its half-life — the engineering trick behind once-weekly dosing.

Its receptor balance is not equal across the three targets. In laboratory assays the discovery team reported balanced glucagon- and GLP-1-receptor activity but more GIP-receptor activity, so it is not simply "one-third each."

Half-life and dosing

Retatrutide's pharmacokinetics support once-weekly subcutaneous injection. The discovery paper notes that its pharmacokinetic profile supported once-weekly dosing, with weight reduction persisting up to 43 days after a single dose, and the phase 1b dosing study used once-weekly injections. The half-life is in the range of about six days. In practice, trials use a gradual dose-escalation schedule rather than starting at a full dose — covered in our retatrutide dosing guide.

Putting it together

Mechanistically, retatrutide is designed to attack body weight from two directions at once:

• Lower energy intake via GLP-1 and GIP — reduced appetite, increased satiety, slowed gastric emptying.
• Raise energy output and shift fat handling via glucagon — increased energy expenditure and hepatic fat oxidation (established in animals, proposed in humans).
• Maintain glucose control by leaning on the insulin-promoting GLP-1/GIP arms to counterbalance glucagon's glucose-raising tendency.

That combination is the theory behind the unusually large weight-loss figures seen in early trials. Whether it holds up — and how its side-effect profile compares — is what the ongoing Phase 3 program is testing.

FAQ

What receptors does retatrutide target?

Three: the GLP-1 receptor, the GIP receptor and the glucagon receptor. That triple activity is why it's called a triple agonist, and it's the key structural difference from tirzepatide, which targets only GLP-1 and GIP.

Why does retatrutide add glucagon activity?

Glucagon-receptor agonism is thought to increase energy expenditure and hepatic fat oxidation, complementing the appetite- and calorie-reducing effects of GLP-1 and GIP. In mouse studies this added energy expenditure augmented weight loss; the contribution in humans is biologically plausible but not yet definitively established.

How often is retatrutide dosed?

In trials it is given as a once-weekly subcutaneous injection. Its pharmacokinetic profile, with a half-life of roughly six days, supports weekly dosing.

Is retatrutide the same as Ozempic or Mounjaro?

No. Semaglutide (Ozempic/Wegovy) is a single GLP-1 agonist and tirzepatide (Mounjaro/Zepbound) is a dual GLP-1/GIP agonist. Retatrutide adds a third target, the glucagon receptor, and is investigational rather than approved.

References

1. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metabolism, 2022.

2. Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multiple-ascending-dose trial. The Lancet, 2022.

3. Li W, Zhou Q, Cong Z, et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery, 2024.

4. Kleinert M, Sachs S, Habegger KM, et al. Glucagon regulation of energy expenditure. International Journal of Molecular Sciences, 2019.